Work

The Bevacizumab Skip in Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma

Year: 2024

Type: article

Abstract: Systemic therapy for unresectable Hepatocellular Carcinoma (u-HCC) has advanced in recent years, particularly immunotherapy. Atezolizumab plus bevacizumab has shown significant survival benefit in u-HCC, and recent AASLD guidelines recommend this regimen as a first-line option.

Source: SciBase Gastroenterology and Hepatology

DOI: 10.52768/scibasegastroenterolhepatol/1005

Author: Tomokazu Kawaoka

Institution: Hiroshima University

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4406083794